Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma

NCT01089101 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01089101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01089101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 7, 2010
Completion date
March 18, 2027
Enrollment
217 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

low grade glioma, recurrent childhood pilocytic astrocytoma, recurrent neurofibromatosis type 1, recurrent visual pathway glioma, refractory neurofibromatosis type 1, refractory visual pathway glioma